Welcome to our dedicated page for Neogen SEC filings (Ticker: NEOG), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Neogen Corporation SEC filings document material events for an operating company focused on food safety and animal safety products. Recent 8-K filings cover quarterly results and financial condition, Regulation FD disclosures related to Petrifilm manufacturing validation, and exhibits containing earnings releases and business updates.
The company’s filings also record governance and leadership matters, including executive appointments and departures, compensatory arrangements, board committee assignments, annual meeting voting results, executive compensation votes, and auditor ratification. These disclosures provide formal records of Neogen’s public-company reporting, operating updates, governance structure and shareholder matters.
Norges Bank, manager of Norway’s sovereign wealth fund, filed Amendment No. 3 to Schedule 13G on Neogen Corp (NEOG) as of 30 Jun 2025. The bank now reports beneficial ownership of 9,076,830 common shares, representing 4.2 % of outstanding stock. All shares are held with sole voting and dispositive power; there is no shared power with other parties.
The filing indicates that Norges Bank’s stake has fallen below the 5 % threshold, activating the “Ownership of 5 Percent or Less” disclosure in Item 5. The shares are held on behalf of the Government of Norway and were acquired in the ordinary course of business, with no intent to influence control of the issuer. Aya Sobhy signed the certification on 24 Jul 2025.
Neogen Corp. (NEOG) filed an 8-K disclosing a leadership change. The Board appointed Mikhael Nassif, age 49, as President & CEO effective 11 Aug 2025. Nassif joins from Siemens Healthineers, where he led the global Point-of-Care Diagnostics unit, and previously held senior posts at Baxter, AB InBev, and Johnson & Johnson. The filing states there are no related-party transactions or pre-existing arrangements tied to the appointment.
Compensation package: (1) Base salary $800k, subject to review; (2) Annual bonus target 100% of salary, payout range 0–250%, eligible for the full FY26 cycle; (3) Annual long-term equity grant targeted at $4.5 m; (4) One-time sign-on equity grant of $2 m (50% options, 50% RSUs, 4-year ratable vesting); (5) One-time cash award $500k payable by 5 Sep 2025, repayable if employment ends within one year; (6) Relocation support with full claw-back in year 1 and 50% in year 2; (7) Standard executive severance and benefit programs. A copy of the offer letter is filed as Exhibit 10.1. The company also issued a press release announcing the appointment.